MedTrace Logo

CyberKnife® for Hepatic Metastases From Colorectal Cancer

NCT01318447 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-04-08

No results posted yet for this study

Summary

This prospective, multicenter study is intended to establish the efficacy and toxicity of treating unresectable colorectal liver metastases with accurately administered radiation using the CyberKnife stereotactic radiosurgery system.

Conditions

  • Colorectal Liver Metastases

Interventions

RADIATION

CyberKnife SBRT

Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.

Sponsors & Collaborators

  • Centre Oscar Lambret

    collaborator OTHER

  • Accuray Incorporated

    lead INDUSTRY

Principal Investigators

  • Xavier Mirabel, MD · Centre Oscar Lambret

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318447 on ClinicalTrials.gov